Form 4: Merit Medical Systems Director Gunderson Receives Stock Grant

Director Thomas James Gunderson received 2,431 restricted stock units from Merit Medical Systems, Inc.

Summary

• Thomas James Gunderson, a director at Merit Medical Systems Inc., received 2,431 restricted stock units (RSUs) on May 16, 2024, under the company's 2018 Long-Term Incentive Plan.
• These RSUs will vest on May 16, 2025, contingent upon Gunderson's continued service to the issuer.
• Gunderson also holds non-qualified stock options to purchase 25,000 shares at $50.50, which become exercisable in installments starting June 7, 2019, and expire on June 7, 2025.
• Additionally, he holds options to buy 13,750 shares at $52.17, exercisable from May 24, 2020, and expiring on May 24, 2026, and options for 7,500 shares at $52.17, exercisable from May 31, 2020, and expiring on May 31, 2026.
• Following the reported transaction, Gunderson beneficially owns 21,688 shares of common stock directly.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a standard practice and indicates confidence in the company's future performance. The director's continued service is incentivized, which is a positive sign.

Positives

• The grant of RSUs aligns the director's interests with the long-term performance of the company.
• The vesting of RSUs is tied to continued service, incentivizing the director's commitment to the company.

Risks

• The value of the RSUs is subject to the market price of Merit Medical Systems' stock, which can fluctuate.
• The vesting of the RSUs is contingent upon continued service, meaning the director must remain with the company to realize their value.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and exercisability schedules of the RSUs and stock options.

Industry Context

Stock grants and options are common forms of executive compensation in the medical device industry, aligning management's interests with shareholder value and incentivizing long-term performance.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, including those in the medical device sector.
• Companies like Medtronic, Boston Scientific, and Stryker also utilize stock options and restricted stock units to incentivize their executives and directors.
• The vesting schedules and exercise prices are generally in line with industry norms, designed to reward long-term value creation.

Stakeholder Impact

• Shareholders may view the stock grant as a positive sign, aligning the director's interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment from the leadership.

Key Dates